SBIR-STTR Award

Development of Aptamer Affinity Reagents to Immune Targets in Non-human Disease Models
Award last edited on: 6/15/20

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$600,000
Award Phase
1
Solicitation Topic Code
NIAID
Principal Investigator
George W Jackson

Company Information

Base Pair Biotechnologies Inc (AKA: Ice Nine Biotechnologies)

8619 Broadway Street Suite 100
Pearland, TX 77584
   (832) 230-5518
   info@basepairbio.com
   www.basepairbio.com
Location: Single
Congr. District: 22
County: Brazoria

Phase I

Contract Number: 75N93019C00049-0-9999-1
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2019
Phase I Amount
$600,000
This goal of this program is to address the limited availability of reagents antibodies proteins ligands for the identification and discrimination of immune cells and the characterization of immune responses in no mammalian models and mammalian models for which immunologic reagents are limited eg guinea pig ferret cotton rat For example the progression of disease that follows infection of guinea pigs with Mycobacterium tuberculosis displays many features of human TB While this model has been used for more than years as a research tool to understand and describe disease mechanisms immunologic analyses are constrained by the limited availability of immunological reagents specific for the guinea pig Another example is the ferret model where immunologic studies also have been limited by the lack of immunological reagents In this project Base Pair Biotechnologies will use its patented process for highly multiplexed aptamer selection to rapidly generate at least new affinity reagents in Phase I to important immune markers in guinea pigs and ferrets Our expert consultant in TB animal models will aid in target selection along with our staff with extensive bioinformatics experience These new reagents will be characterized for their binding constants specificity and demonstrated in ELISA like assays and ELI Spot In Phase II we will use the same process to generate at least more reagents and employed in additional applications relevant to cancer immunology studies and clinical trials

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----